Nuclea Biotechnologies, LLC, cofounded by President and Chief Executive Officer Patrick Muraca in 2005, creates new medical technology designed for refining disease diagnosis and treatment. Utilizing traceable genetic components accompanying diseases, the company offers new resources for clinicians in selecting treatments and predicting prognoses. Nuclea maintains headquarters in Pittsfield, Massachusetts, with additional research facilities in Worcester, Massachusetts. Patrick Muraca and the leadership at Nuclea Biotechnologies pursue the overarching goal of shortening the diagnostic process for many life-threatening disorders, allowing larger treatment windows and more informed treatments. Since its beginning, Nuclea has introduced over 30 diagnostic tests, all based on genetic evidence available through emerging technology. Through its specialized DecisionDx database, Nuclea Biotechnologies possesses the ability to integrate medical data analyses with cell analyses from Tissue MicroArrays, predict patient responses to treatment, and predict a patient's particular risk of side effects from a treatment. Other resources aiding innovation at Nuclea include a clinical database that allows researchers to isolate protein expression patterns, or gene signatures, associated with specific diseases. Nuclea Biotechnologies additionally utilizes a vast biorepository of clinical tissue samples. By gathering data on genetic expression characteristics observed in tissue samples and combining it with documented patient data, Nuclea gains further advantages in analyzing common genetic properties accompanying disorders at different stages of illness. Other technology at Nuclea Biotechnologies' disposal includes database-driven access to numerous gene sequence analysis programs, complete with statistical and specialized search resources. Due to the large amount of data required for analyzing gene expression characteristics, Nuclea Biotechnologies seeks to add new database organization options to its already sophisticated computing system, including strategically combined collections of Tissue MicroArrays representing specific diseases and additional options for integration with clinical information.